Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Takeda moves ahead in...

    Takeda moves ahead in Zika race with launch of vaccine trial

    Written by Ruby Khatun Khatun Published On 2017-11-30T09:30:26+05:30  |  Updated On 18 Aug 2021 2:54 PM IST

    LONDON: Japan's Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical trial program backed by the U.S. government.


    Its French rival Sanofi had initially been viewed as the large drugmaker best placed to bring the first vaccine to market when Zika erupted as a major public health hazard in Brazil in 2015.



    But making such a vaccine proved more difficult than hoped and the U.S. Department of Health and Human Services' development arm BARDA reduced support for Sanofi's project, causing it to end development efforts in September.

    Both Takeda and Sanofi have been working on similar vaccines using inactivated or killed whole Zika virus. This type of vaccine has been widely used to protect against a range of diseases and has a good safety record.


    Other small biotech companies are working on a more experimental approach focused on DNA-based vaccines, which are made by reproducing sections of the Zika virus genome in a lab.


    Takeda said on Tuesday it expected results next year from its 240-patient Phase I Zika vaccine clinical trial, which is taking place in the continental United States and U.S. territories.


    The World Health Organization declared the Zika outbreak a public health emergency of international concern in February 2016, although it has since downgraded the threat. However, Zika remains a significant public health risk, especially for pregnant women, and a vaccine is still needed.


    Two years ago, when Zika was making headlines after causing thousands of birth defects in Brazil, scientists were predicting a vaccine might be produced in record time, perhaps before the end of the decade.


    But current development timelines suggest one won't be ready until the 2020s. Even if Takeda's shot succeeds in Phase I studies, it will still need to progress through two further stages of testing before it is ready for regulatory approval.


    For the Japanese company, developing a Zika vaccine is an important milestone in proving its vaccines division can compete with global players.


    Takeda also has a vaccine in late-stage development against dengue fever - another mosquito-borne virus with similarities to Zika - that will compete against Sanofi's Dengvaxia, the first dengue vaccine to reach the market.




    (Reporting by Ben Hirschler. Editing by Jane Merriman)



    aheadClinical TrialDengvaxiaDNA-based vaccinesLaunchpharma newsSanofiTakedaTakeda PharmaceuticalTakeda Pharmaceutical Co Ltdvaccinevaccine trialWorld Health OrganizationZikazika virus
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok